Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 8/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.54 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 6/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | ROS1 | P08922 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | PRKX | P51817 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29449786 | 0.84 | CYP11B1 (0.59) | CYP11B1CYP11B2PRKCZAKT1PIM1 | |
| SCHEMBL28933997 | 0.84 | CYP11B1 (0.59) | CYP11B1CYP11B2PRKCZAKT1PIM1 | |
| SCHEMBL15514747 | 0.78 | PRKCZ (0.55) | CYP11B1CYP11B2PRKCZAKT1PIM1 | |
| SCHEMBL444504 | 0.77 | PRKCZ (0.63) | CYP11B1CYP11B2PRKCZAKT1PIM1 | |
| SCHEMBL17691836 | 0.76 | PRKCZ (0.56) | CYP11B1CYP11B2PRKCZAKT1PIM1 | |
| SCHEMBL18891280 | 0.76 | CYP11B1 (0.69) | CYP11B1CYP11B2PRKCZAKT1CYP19A1 | |
| SCHEMBL29547785 | 0.75 | CYP11B1 (0.56) | CYP11B1CYP11B2PRKCZPIM1CDK5 | |
| SCHEMBL484716 | 0.75 | CYP11B1 (0.56) | CYP11B1CYP11B2PRKCZPIM1CDK5 | |
| SCHEMBL5115735 | 0.75 | CYP2A6 (0.60) | CYP11B1CYP11B2ROCK2ROCK1CYP17A1 | |
| SCHEMBL6355545 | 0.74 | CYP11B2 (0.61) | CYP11B1CYP11B2PRKCZAKT1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | CYP11B1 1815/4885CYP11B2 2437/4885PRKCZ 160/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | CYP11B1 1815/4885CYP11B2 2437/4885PRKCZ 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.